Business acquisition - Narrative (Details) - USD ($) $ in Thousands		1 Months Ended			3 Months Ended		6 Months Ended
	Dec. 01, 2021	Jan. 31, 2022	Dec. 31, 2021	Dec. 31, 2021	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Business Acquisition [Line Items]
Income tax benefit					$ (149)	$ 61	$ (10,554)	$ 107
Abveris
Business Acquisition [Line Items]
Fair value of consideration transferred	$ 102,645
Cash consideration	$ 9,467
Equity (in shares)	759,601
Common stock	$ 66,100
Options consisderation	6,400
Contingent consideration	8,500
Indemnity holdbacks	12,800
Net working capital adjustment	$ 674
Contingent consideration, shares issuable up to (in shares)	334,939
Indemnity holdbacks period	18 months
Indemnity holdback shares (in shares)	128,351
Indemnity holdback options (in shares)	15,304
Indemnity holdback consideration	$ 12,500
Adjustment holdback shares (in shares)	3,416
Adjustment holdback options (in shares)	408
Value of adjustment holdback	$ 300
Post combination compensation expenses includes employee stock awards			$ 41,000
Vesting period from acquisition date	2 years
Discount rate					9.60%		9.60%
Transaction costs							$ 1,500
Change in fair value during the period				$ 8,066			(8,100)
Income tax benefit							$ 10,500
Company common stock	$ 72,514
Abveris | Awards with vesting requirements
Business Acquisition [Line Items]
Post combination compensation expenses includes employee stock awards			$ 17,700
Vesting period from acquisition date			2 years
Abveris | Awards without vesting requirements
Business Acquisition [Line Items]
Post combination compensation expenses includes employee stock awards			$ 3,200
Abveris | Performance Shares
Business Acquisition [Line Items]
Post combination compensation expenses includes employee stock awards			$ 20,100
iGenomX
Business Acquisition [Line Items]
Contingent consideration (in shares)			59,190
Company common stock		$ 4,600